



Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
		Application Number			
		Filing Date			
		First Named Inventor		Mark L. Tykocinski	
		Group Art Unit			
		Examiner Name			
		Attorney Docket Number		285332-00002-2-2	
Sheet	2	of	2		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	G	ELAINE B. BRUNSCHWIG et al.; "Glycosylphosphatidylinositol-Modified Murine B7-1 and B7-2 Retain Costimulator Function"; <i>The Journal of Immunology</i> ; 1995; pp.5498-5505; 155; American Association of Immunologists; Bethesda, Maryland, USA	
	H	REBECCA S. MCHUGH et al.; "Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80)"; <i>Proceedings of the National Academy of Sciences of the USA</i> ; August 1995; pp.8059-8063; 92; National Academy of Sciences; Washington, D.C.; USA	
	I	REBECCA S. MCHUGH et al.; "Protein Transfer of Glycosyl-phosphatidylinositol-B7-1 into Tumor Cell Membranes: A Novel Approach to Tumor Immunotherapy"; <i>Cancer Research</i> ; May 15, 1999; pp.2433-2437; 59; American Association for Cancer Research, Philadelphia, Pennsylvania, USA	
	J	STANLEY A. KIM et al.; "The use of palmitate-conjugated protein A for coating cells with artificial receptors which facilitate intercellular interactions"; <i>Journal of Immunological Methods</i> ; 1993; pp.57-65; 158; Elsevier Science Publishers B.V., Amsterdam, The Netherlands	
	K	JOSEPH H. PHILLIPS et al.; "CD94 and a Novel Associated Protein (94AP) Form a NK Cell Receptor Involved in the Recognition of HLA-A, HLA-B, and HLA-C Allotypes"; <i>Immunity</i> ; August 1996; pp.163-172; 5; Cell Press, Cambridge, Massachusetts, USA	
	L	D. DARLING et al.; "In vitro immune modulation by antibodies coupled to tumour cells"; <i>Gene Therapy</i> ; 1997; pp.1350-1360; 4; Nature Publishing Group, London, United Kingdom	
	M	THOMAS R. LONDO et al.; "Lateral Diffusion of Antigen Receptors Artificially Incorporated onto B Lymphocytes"; <i>The Journal of Immunology</i> ; Sept. 15, 1986; pp.1924-1931; 6; American Association of Immunologists; Bethesda, Maryland, USA	
	N	JAMES S. PEACOCK et al.; "Biologic Activity of Antigen Receptors Artificially Incorporated onto B Lymphocytes"; <i>The Journal of Immunology</i> ; Sept. 15, 1986; pp.1916-1923; 6; American Association of Immunologists; Bethesda, Maryland, USA	
	O	ARTHUR S. COLSKY et al.; "A Method for "Custom Designing" Killer Cells of Desired Target Specificity"; <i>The Journal of Immunology</i> ; Apr. 15, 1988; pp.2515-2519; 140; American Association of Immunologists; Bethesda, Maryland, USA	
	P	ARTHUR S. COLSKY et al.; "Palmitate-derivatized antibodies can function as surrogate receptors for mediating specific cell-cell interactions"; <i>Journal of Immunological Methods</i> ; 1989; pp.179-187; 124; Elsevier Science Publishers B.V., Amsterdam, The Netherlands	
	Q	POLLY MATZINGER; "The JAM Test: A simple assay for DNA fragmentation and cell death"; <i>Journal of Immunological Methods</i> ; 1991; pp.185-192; 145; Elsevier Science Publishers B.V., Amsterdam, The Netherlands	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.